http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021322399-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a80cbaaeee718664126e579cf4e41c2 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
filingDate | 2021-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0dbcc7f4b4d5333f54cf6c92b6eee7e |
publicationDate | 2021-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2021322399-A1 |
titleOfInvention | Treatment of schizophrenia |
abstract | Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions. |
priorityDate | 2015-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.